PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study

PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study

Abstract Programmed cell death receptor ligand-1 (PD-L1) expression, KRAS (KRASm) and EGFR (EGFRm) mutations may influence non-small cell lung cancer (NSCLC) prognosis. We aimed to evaluate PD-L1 expression, KRASm, and EGFRm and survival among stage III unresected NSCLC patients. Using Danish regist...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Deirdre Cronin-Fenton, Tapashi Dalvi, Naimisha Movva, Lars Pedersen, Hanh Hansen, Jon Fryzek, Elizabeth Hedgeman, Anders Mellemgaard, Torben R. Rasmussen, Norah Shire, Stephen Hamilton-Dutoit, Mette Nørgaard
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/b4c1a9ab9ce54222a8cc1b0d41e549b9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/b4c1a9ab9ce54222a8cc1b0d41e549b9

Ejemplares similares